The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia

Figures & data

Table 1. Characteristics of patients.

	N = 21
Age, years, median, (range)	44(18−74)
Male, n (%)	15(71.4)
Female,n (%)	6(28.6)
Disease phase at diagnosis, n (%)
Chronic	20 (95.2)
Blast	1 (4.8)
Blood counts at initial diagnosis(range)
WBC (×10^9/L)	258.42 (17.8−553.6)
PLT(×10^9/L)	557.62 (102−1021)
Hb (g/L)	94.29 (71−147)
Spleen size(subcostal, cm)(range)	5.78 (0−12.5)
Sokal score,n (%)
Low	8 (38.1)
Intermediate	8 (38.1)
High	5 (23.8)
ELTs score,n (%)
Low	13 (61.9)
Intermediate	7 (33.3)
High	1 (4.8)
Number of TKI before eltrombopag
1	15 (71.4)
2	4 (19.0)
4	2 (9.5)
Last TKI before eltrombopag
Imatinib	8 (38.1)
Dasatinib	5 (23.8)
Nilotinib	2 (9.5)
Flumatinib	2 (9.5)
Ponatinib	1 (4.8)
Olverembatinib	3 (14.3)
TKI duration, mo, median (range)	20.6 (1.1−199)
Response, n (%)
CCyR	1(4.8)
PCyR	7 (33.3)
mCyR	12 (57.1)
noCyR	2 (9.5)
Comorbidity, n (%)
Yes	3 (14.3)
No	19 (85.7)

TKI: tyrosine kinase inhibitors; CCyR: complete cytogenetic remission; mCyR; minor cytogenetic remission; PCyR: partial cytogenetic remission.

Figure 1. The effect of Eltrombopag on blood count. PLT: Platelets; HGB: hemoglobin; WBC: White Blood Cells.

Table 2. TKI and Eltrombopag treatment.

N	TKI before eltrombopag	Treatment before eltrombopag	PLT before etrombopag (×10^9/L)	Dose of eltrombopag (mg)	Duration of eltrombopag (day)	PLT after eltrombopag(×10^9/L)
1	Dasatinib, Flumatinib	IL-11 (1.5 mg/d × 7d)	9	50–75	14	234
2	Dasatinib Nilotinib	IL-11 (1.5 mg/d × 10d)	23	25–50	60	53
3	Dasatinib Flumatinib	IL- 11 (1.5 mg/d × 7d) rhTPO (15000iu/d × 15d)	28	25	44	94
4	Imatinib Nilotinib	rhTPO (15000iu/d × 16d) IL-11 (1.5 mg/d × 3d) Methylprednisolone (20 mg/d × 14d)	22	25–50	360	88
5	Imatinib	Methylprednisolone (20 mg/d × 21d) Immunoglobulin (10 g/d × 7d) Dexamethasone (5 mg/d × 7d)	24	50–75	120	178
6	Nilotinib	rhTPO (15000iu/d × 7d) Caffeic acid tablet (0.9 g/d × 60d)	2	25	14	460
7	Imatinib	Caffeic acid tablet (0.9 g/d × 105d) rhTPO (15000iu/d × 14d) Dexamethasone (40 mg/d × 4d)	16	25–75	285	66
8	Flumatinib	Caffeic acid tablet (0.9 g/d × 30d)	23	25–50	120	146
9	Nilotinib	Caffeic acid tablet (0.9 g/d × 60d) Prednisone (30 mg/d × 50d)	19	50–100	135	103
10	Imatinib Dasatinib	Caffeic acid tablet (0.9 g/d × 180d)	14	25	60	51
11	Imatinib Dasatinib Nilotinib	rhTPO (15000iu/d × 21d) Immunoglobulin (25 g/d × 4d) Prednisone (60 mg/d × 14d)	8	50–75	120	115
12	Dasatinib Olverembatinib	rhTPO (15000iu/d × 7d)	6	50	28	91
13	Imatinib Dasatinib Nilotinib Olverembatinib	rhTPO (15000iu/d × 7d)	3	50–75	48	133
14	Imatinib Dasatinib, Nilotinib Olverembatinib Flumatinib	rhTPO (15000iu/d × 10d)	15	50–75	28	91
15	Dasatinib	No	25	25	18	257
16	Dasatinib	No	10	50–75	120	162
17	Dasatinib Ponatinib	rhTPO (15000iu/d × 18d) Danazol (0.6 g/d × 300d) Prednisone (10 mg/d × 60d)	12	50	30	14
18	Dasatinib	rhTPO (15000iu/d × 9d)	3	50–100	120	19
19	Imatinib, Flumatinib	rhTPO 15000iu/d × 10d IL- 11 1.5 mg/d × 7d	27	25–50	48	5
20	Imatinib, Dasatinib	rhTPO 15000iu/d × 10d IL-11 1.5 mg/d × 7d	24	50	30	38
21	Imatinib	No	14	50	42	41

TKI: tyrosine kinase inhibitors; PLT : Platelets

Table 3. TKI response before and after treatment with Eltrombopag.

No	TKI at last follow-up	Dose (mg)	Ph + (%)		BCR/ABL(IS) (%)
			Before	After	Before	After
1	Flumatinib	200	60		51.820
2	Nilotinib	400	35	30	16.000	22.10
3	Flumatinib	400	75		16.210
4	Nilotinib	400	65	0	11.350	6.810
5	Imatinib	400	58	0	51.240	0.385
6	Nilotinib	600	96		103.320
7	Imatinib	400	5	0	2.681	0.681
8	Flumatinib	600	40	0	22.450	0.123
9	Imatinib	400	96	64	79.120	16.560
10	Dasatinib	70	16	0	8.426	2.467
11	Nilotinib	400	35	10	15.270	9.895
12	Olverembatinib	40	35	32	22.670	23.510
13	Olverembatinib	30	55	22	27.525	23.518
14	Flumatinib	600	38	15	29.250	8.6687
15	Dasatinib	100	77	0	69.778	0.939
16	Dasatinib	100	90	55	69.892	23.176
17	No		10		8.955	7.098
18	No		85		79.670
19	No		75		52.788
20	Dasatinib	50	65		45.580
21	Nilotinib	400	25		23.764

TKI: tyrosine kinase inhibitors; The results of Ph (%) and BCR/ABL(IS) before and after treatment were as follows: test results within 3 months before treatment and reexamination results within 3–6 months after treatment.